Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect

Clinical Cancer Research

Volumn 9, Issue 4, 2003, Pages 1566-1572

  Tortora, Giampaolo ^a   Caputo, Rosa ^a   Damiano, Vincenzo ^a   Melisi, Davide ^a   Bianco, Roberto ^a   Fontanini, Gabriella ^b   Veneziani, Bianca Maria ^a   De Placido, Sabino ^a   Bianco, A Raffaele ^a   Ciardiello, Fortunato ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR; GEFITINIB; OLIGONUCLEOTIDE; RNA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG SELECTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE CANCER; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR XENOGRAFT;

AGAR; ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, WESTERN; CELL LINE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDES, ANTISENSE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROTEIN-TYROSINE KINASES; PYRAZOLES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SULFONAMIDES;

EID: 0037386939     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Ciardiello, F., and Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res., 7: 2958-2970, 2001.
2. Cho-Chung, Y. S., Pepe, S., Clair, T., Budillon, A., and Nesterova, M. cAMP-dependent protein kinase: role in normal and malignant growth. Crit. Rev. Oncol. Hematol., 21: 33-61, 1995.
3. Woodburn, J. R. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther., 82: 241-250, 1999.
4. Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Pomatico, G., De Placido, S., Bianco, A. R., and Tortora, G. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor. Clin. Cancer Res., 6: 2053-2063, 2000.
5. Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Fontanini, G., Cuccato, S., De Placido, S., Bianco, A. R., and Tortora, G. Inhibition of growth factors production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res., 7: 1459-1465, 2001.
6. Tortora, G., and Ciardiello, F. Targeting of epidermal growth factor receptor and protein kinase A: molecular basis and therapeutic applications. Ann. Oncol., 11: 777-783, 2000.
7. Tortora, G., Damiano, V., Bianco, C., Baldassarre, G., Bianco, A. R., Lanfrancone, L., Pelicci, P. G., and Ciardiello, F. The RIα subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. Oncogene, 14: 923-928, 1997.
8. Tortora, G., and Ciardiello, F. Protein kinase a type I: a target for cancer therapy. Clin. Cancer Res., 8: 303-304, 2002.
9. Nesterova, M., and Cho Chung, Y. S. A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth. Nat. Med., 1: 528-533, 1997.
10. Tortora, G., Caputo, R., Damiano, V., Bianco, R., Pepe, S., Bianco, A. R., Jiang, Z., Agrawal, S., and Ciardiello, F. Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. Proc. Natl. Acad. Sci. USA, 94: 12586-12591, 1997.
11. Wang, H., Cai, Q., Zeng, X., Yu, D., Agrawal, S., and Zhang, R. Antitumor activity and pharmacokinetics of a mixed-backbone oligonucleotide targeted to the RIα subunit of protein kinase A following oral administration. Proc. Natl. Acad. Sci. USA, 96: 13989-13994, 1999.
12. Tortora, G., Bianco, R., Damiano, V., Fontanini, G., De Placido, S., Bianco, A. R., and Ciardiello, F. Oral antisense targeting protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis and growth factors production. Clin. Cancer Res., 6: 2506-2512, 2000.
13. Ciardiello, F., Damiano, V., Bianco, R., Bianco, C., Fontanini, G., De Laurentiis, M., De Placido, S., Mendelsohn, J., Bianco, A. R., and Tortora, G. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J. Natl. Cancer Inst. (Bethesda), 88: 1770-1776, 1996.
14. Turini, M. E., and DuBois, R. N. Cyclooxygenase-2: a therapeutic target. Annu. Rev. Med., 53: 35-57, 2002.
15. Masunaga, R., Kohno, H., Dhar, D. K., Ohno, S., Shibakita, M., Kinugasa, S., Yoshimura, H., Tachibana, M., Kubota, H., and Nagasue, N. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin. Cancer Res., 6: 4064-4068, 2000.
16. Kulkarni, S., Rader, J. S., Zhang, F., Liapis, H., Koki, A. T., Masferrer, J. L., Subbaramaiah, K., and Dannenberg, A. J. Cyclooxygenase-2 is overexpressed in human cervical cancer. Clin. Cancer Res., 7: 429-434, 2001.
17. Khuri, F. R., Wu, H., Lee, J. J., Kemp, B. L., Lotan, R., Lippman, S. M., Feng, L., Hong, W. K., and Xu, X-C. Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin. Cancer Res., 7: 861-867, 2001.
18. Masferrer, J. L., Leahy, K. M., Koki, A. T., Zweifel, B. S., Settle, S. L., Woerner, M., Edwards, D. A., Flickinger, A. G., Moore, R. J., and Seibert, K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res., 60: 1306-1311, 2000.
19. Rudnick, D. A., Perlmutter, D. H., and Muglia, L. J. Prostaglandins are required for CREB activation and cellular proliferation during liver regeneration. Proc. Natl. Acad. Sci., USA, 98: 8885-8890, 2001.
20. Torrance, C. J., Jackson, P. E., Montgomery, E., Kinzler, K. W., Vogelstein, B., Wissner, A., Nunes, M., Frost, P., and Discafani, C. M. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med., 6: 1024-1028, 2000.
21. Masferrer, J. L., Koki, A., and Seibert, K. COX-2 inhibitors. A new class of antiangiogenic agents. Ann. N. Y. Acad. Sci., 889: 84-86, 1999.
22. Agrawal, S., and Zhao, Q. Antisense therapeutics. Curr. Opin. Chem. Biol., 2: 519-528, 1998.
23. Weidner, N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res. Treat., 36: 169-180, 1995.
24. Schmitt, F. C., and Soares, R. TGFα and angiogenesis. Am. J. Surg. Pathol., 23: 358-359, 1999.
25. Gille, J., Swerlick, R. A., and Caughman, S. W. Transforming growth factor α-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP2-dependent DNA binding and transactivation. EMBO J., 16: 750-759, 1997.
26. Bianco, C., Tortora, G., Baldassarre, G., Caputo, R., Fontanini, G., Chinè, S., Bianco, A. R., and Ciardiello, F. 8-chloro-cAMP inhibits autocrine and angiogenic growth factor production in human colorectal and breast cancer. Clin. Cancer Res., 3: 439-448, 1997.
27. Tsujii, M., Kawano, S., Tsujii, S., Sawaoka, H., Hori, M., and DuBois, R. N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 93: 705-716, 1998.
28. Tsujii, M., Kawano, S., and DuBois, R. N. Cyclooxygenase-2 expression in colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci., USA, 94: 3326-3340, 1997.
29. Gately, S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev., 19: 19-27, 2000.
30. Tortora, G., Caputo, R., Damiano, V., Fontanini, G., Melisi, D., Veneziani, B. M., Zunino, F., Bianco, A. R., and Ciardiello, F. Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity. Clin. Cancer Res., 7: 4156-4163, 2001.
31. Castano, E., Bartrons, R., and Gil, J. Inhibition of cyclooxygenase-2 decreases DNA synthesis induced by platelet-derived growth factor in Swiss 3T3 fibroblasts. J. Pharmacol. Exp. Ther., 293: 509-513, 2000.